Scynexis-Color.png
SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement
April 13, 2020 08:54 ET | Scynexis
SCYNEXIS has the ability, at its discretion, to efficiently access up to $20 million of capital $20 million purchase agreement, combined with $10 million cash injection from recent sale of...
Scynexis-Color.png
SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital
April 09, 2020 08:53 ET | Scynexis
JERSEY CITY, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
Scynexis-Color.png
SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020
March 26, 2020 08:00 ET | Scynexis
JERSEY CITY, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
Scynexis-Color.png
SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update
March 11, 2020 08:18 ET | Scynexis
Oral ibrexafungerp continues to advance in multiple indicationsNearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more...
Scynexis-Color.png
SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference
March 05, 2020 08:00 ET | Scynexis
Preclinical in vitro data showed synergistic activity against Aspergillus isolates from lung transplant recipientsSCYNEXIS is conducting two clinical trials for patients suffering from Aspergillus...